United Therapeutics Corp (UTH.DU)
| Previous Close | 296.20 |
| Open | 293.10 |
| Bid | 292.90 x N/A |
| Ask | 296.90 x N/A |
| Day's Range | 293.10 - 293.10 |
| 52 Week Range | 190.85 - 301.40 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireUnited Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., June 27, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was elected by the company’s shareholders at its annual meeting held on June 26, 2024.
- Business Wire
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., June 05, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida.
Simply Wall St.Investing in United Therapeutics (NASDAQ:UTHR) five years ago would have delivered you a 213% gain
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
